B+
Bull case
25%
Probability
Target price
$8.50
+99.1% vs current
AVIR
AteaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$5.00
+17.1% vs current
B-
Bear case
30%
Probability
Target price
$2.20
-48.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-15
Recent news sentiment (30D)
+50.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+67.0
Score
AI commentary
This T+3 earnings follow-up still reads as a monitoring setup rather than a thesis upgrade. The May 12 company source reaffirmed trial timing and runway but did not provide new clinical data, and checked evidence did not surface a clear delayed analyst target or estimate revision after the print. Secondary coverage described the immediate market reaction as subdued, and the packet's May 14 anchor close was $4.27, suggesting investors are waiting for the mid-2026 C-BEYOND readout instead of rewarding the quarter itself. Peer context remains tentative because the most relevant operating benchmarks are large HCV incumbents, not close small-cap biotech peers.
RankAlpha Sentiment Codex - 2026-05-15
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-07-01eventC-BEYOND Phase 3 topline remains the key mid-2026 inflectionHigh impact
In its May 12 earnings update, Atea reaffirmed that C-BEYOND in North America was fully enrolled in December 2025 with more than 880 patients and that topline results are still expected in mid-2026, leaving the stock largely tethered to a single near-term binary readout [#8-K-2026-05-12] [#10-Q-2026-05-12].
2026-07-01eventAT-587 Phase 1 start could add a second clinical program in mid-2026High impact
Atea said AT-587 was selected as the lead HEV candidate and that first-in-human Phase 1 initiation is expected in mid-2026, which could modestly broaden the narrative beyond HCV but remains early-stage relative to the Phase 3 value driver [#8-K-2026-05-12] [#10-Q-2026-05-12].
2026-12-31catalystC-FORWARD and March 2027 NDA path extend the HCV thesis beyond the first readoutHigh impact
The Q1 filing says C-FORWARD enrollment is expected to complete in mid-2026 with topline results around year-end 2026, and management is targeting a March 2027 NDA submission if Phase 3 results are successful, which supports a multi-step HCV timeline rather than a one-event story [#10-Q-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-15 • Updated nightlySource: Internal modelMethodology